Tumor-informed circulating tumor DNA stratifies recurrence risk and survival in anal squamous cell carcinoma - PubMed
2 days ago
- #ctDNA
- #ASCC
- #biomarker
- Tumor-informed circulating tumor DNA (ctDNA) assay (Signatera™) was evaluated in a real-world cohort of 84 adults with non-metastatic anal squamous cell carcinoma (ASCC).
- ctDNA was positive in 79% of patients at pre-treatment, including 89% with stage III disease.
- End-of-treatment ctDNA positivity was associated with inferior one-year outcomes: 63% overall survival, 44% progression-free survival, and 39% locoregional failure.
- Patients who were ctDNA-negative at baseline or cleared ctDNA during treatment had 100% locoregional failure-free survival.
- During surveillance, ctDNA re-emergence preceded clinical or radiographic relapse in every case.
- The study supports ctDNA as a dynamic biomarker for risk-adapted surveillance and adjuvant therapy in ASCC.